Washington, DC, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Only two CEOs at the six largest publicly traded health insurers saw their total compensation increase in 2020 compared with 2019 — Cigna Corp.’s David Cordani, and Anthem, Inc.’s Gail Boudreaux — while the other four saw decreases. Some Blue Cross Blue Shield insurers, however, gave their chief executives sizeable pay hikes, including a 109% raise for Blue Cross Blue Shield of Minnesota’s Craig Samitt, and a 73% bump for Independence Blue Cross’ now-retired Daniel Hilferty.
That’s according to Health Plan Weekly, published by AIS Health, the journalism division of Managed Markets Insight & Technology, LLC. (MMIT). The report is based on AIS Health’s annual collection of compensation data for the country’s largest health insurance companies by commercial risk enrollment.
For perennial top earner Michael Neidorff of Centene, a bump in base salary does not necessarily mean a rise in overall annual compensation. Neidorff saw his salary rise from $1.5 million in 2019 to $1.8 million in 2020, but his overall compensation dropped 5.6% year over year, from $26.4 million to $24.9 million.
While the compensation increases at Blue Cross Blue Shield of Minnesota and Independence stand out from the pack, other CEOs at non-publicly traded insurers received less eye-popping but still-significant raises. Blue Cross Blue Shield of Arizona’s Pamela Kehaly, for example, saw her total compensation rise 24.5%, from $2.7 million in 2019 to $3.3 million in 2020. And EmblemHealth Plan, Inc. CEO Karen Ignagni — who once was the CEO of insurer trade group America’s Health Insurance Plans — got a 66.6% compensation boost year over year.
Health Plan Weekly provides in-depth analysis of the trends affecting health insurers’ market share, profitability and regulation, and the strategies they use to respond. This weekly publication covers strategic business, financial and regulatory analysis relevant to health insurers, pharmaceutical companies, health systems, benefits managers and analysts.
About MMIT
For nearly two decades MMIT has been solely focused on solving the “what and why” of market access, and has been a trusted, go-to-market partner to more than 1,300 biopharma and payer customers. We believe that patients who need lifesaving treatments shouldn’t face delays because accessing drugs can be confusing. As the leading provider of market access data, analytics and insights, our expert teams of clinicians, data specialists and market researchers provide clarity and confidence so that our clients can make better decisions.
Divisions of MMIT include AIS Health, creator of the Directory of Health Plans and leading healthcare publications; Zitter Health Insights, provider of market access insights and solutions for specialty drugs; RJ Health, the market leader in pricing and coding solutions for infusion drugs covered under the medical benefit; and The Dedham Group, the preeminent U.S. market access oncology and specialty therapeutics consultancy.
For more information about MMIT, visit mmitnetwork.com and follow us on LinkedIn.
